A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix
Test CodeDRVTS
Alias/See Also
15780
CPT Codes
85613
Includes
If dRVVT Screen is prolonged (>45 seconds), then dRVVT Confirm will be performed at an additional charge (CPT code(s): 85597).
If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed at an additional charge (CPT code(s): 85613).
If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed at an additional charge (CPT code(s): 85613).
Preferred Specimen
1 mL frozen platelet-poor plasma collected in a 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Instructions
Please submit a separate, frozen vial for each special coagulation assay ordered. Draw blood in a light blue-top tube containing 3.2% sodium citrate, mix gently by inverting 3-4 times. Centrifuge 15 minutes at 1500 g within one hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial(s). Freeze immediately and transport on dry ice.
Transport Container
Plastic vial
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 90 days
Refrigerated: Unacceptable
Frozen: 90 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis
Methodology
Clot Detection
Setup Schedule
Set up: Mon-Fri; Report available: 3-6 days after receipt at the performing laboratory. Add two (2) days for transport.
Reference Range
dRVVT Screen | ≤45 seconds |
dRVVT Confirm | Negative |
dRVVT 1:1 Mix | Corrected |
Clinical Significance
The dilute Russell Viper Venom time integrated test is a sensitive method for the detection of Lupus Anticoagulants (LA). LA are autoantibodies that target protein-phospholipid complexes and are found in a variety of clinical conditions. In some patients, a confirmed positive result is associated with an increased thrombotic risk, and is often found in women who have recurrent fetal loss. As Lupus anticoagulants reflect a heterogenous group of antibodies, international consensus guidelines on testing require at least two screening assays be used for a complete evaluation. Refer to Lupus Anticoagulant Comprehensive Evaluation which includes the DRVVT plus a second pathway of testing, the PTT-LA with reflex to Hexagonal Phase Confirm and Thrombin Time.
Note: Target specific anticoagulant therapy (anti-XA, anti-thrombin) may cause false positive results.
Note: Target specific anticoagulant therapy (anti-XA, anti-thrombin) may cause false positive results.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: June 22, 2023